Pacira Pharma (PCRX) Misses Q3 EPS by 83c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts PCRX Hot Sheet
Join SI Premium – FREE
Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of ($0.02), $0.83 worse than the analyst estimate of $0.81. Revenue for the quarter came in at $167.5 million versus the consensus estimate of $171.24 million.
For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald's posts better-than-expected third-quarter comparable sales
- Option Care Health (OPCH) Reports In-Line Q3 EPS
- SmartRent (SMRT) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
